Transition of thyroid autoantibodies by rituximab treatment for thyroid MALT lymphoma

Endocrine Journal

Volumn 58, Issue 1, 2011, Pages 7-12

  Kahara, Toshio ^a   Iwaki, Noriko ^a   Kaya, Hiroyasu ^a   Kurokawa, Toshiro ^a   Yoshida, Takashi ^a   Ishikura, Kazuhide ^a   Usuda, Rika ^a  

^a TOYAMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Hashimoto's thyroiditis; Rituximab; Thyroid autoantibody; Thyroid MALT lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 2 RECEPTOR; LEVOTHYROXINE; PIRARUBICIN; PREDNISOLONE SODIUM SUCCINATE; RITUXIMAB; THYROID ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER GRADING; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DRUG RESPONSE; FEMALE; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; LABORATORY TEST; LARYNX CANCER; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; RECURRENT CANCER; SENSORY DYSFUNCTION; THYROID CANCER; THYROID FUNCTION;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HASHIMOTO DISEASE; HUMANS; IODIDE PEROXIDASE; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDNISONE; THYROID GLAND; THYROID NEOPLASMS; THYROXINE; VINCRISTINE;

EID: 79251647230     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-166     Document Type: Article

References (24)

1. Staunton MD, Greening WP (1973) Clinical diagnosis of thyroid cancer. Br Med J 4: 532-535.
2. Thieblemont C, Mayer A, Dumontet C, Barbier Y, Callet-Bauchu E, Felman P, Berger F, Ducottet X, Martin C, Salles G, Orgiazzi J, Coiffier B (2002) Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab 87: 105-111.
3. Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL (2000) Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol 24: 623-639.
4. Holm LE, Blomgren H, Löwhagen T (1985) Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 312: 601-604.
5. Isaacson PG (1997) Lymphoma of the thyroid gland. Curr Top Pathol 91: 1-14.
6. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195.
7. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18: 3135-3143.
8. Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, Morishima Y, Murate T, Kasai M, Uike N, Taniwaki M, Kano Y, Ohnishi K, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K; IDEC-C2B8 Study Group in Japan (2002) Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 13: 928-943.
9. El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L (2007) B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 92: 1769-1772.
10. El Fassi D, Clemmensen O, Nielsen CH, Silkiss RZ, Hegedüs L (2007) Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease. J Clin Endocrinol Metab 92: 3762-3763.
11. Katoh N, Matsuda M, Ishii W, Morita H, Ikeda S (2010) Successful treatment with rituximab in a patient with stiff-person syndrome complicated by dysthyroid ophthalmopathy. Intern Med 49: 237-241.
12. El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, Nielsen CH (2009) Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 130: 252-258.
13. Raterman HG, Simsek S, Lems WF, Meesters EW, Dijkmans BA, Nurmohamed MT (2009) Rituximab and thyroid function. Arch Intern Med 169: 1073-1074.
14. Salvi M, Vannucchi G, Campi I, Currò N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P (2007) Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156: 33-40.
15. Romaldini JH, Biancalana MM, Figueiredo DI, Farah CS, Mathias PC (1996) Effect of L-thyroxine administration on antithyroid antibody levels, lipid profile, and thyroid volume in patients with Hashimoto's thyroiditis. Thyroid 6: 183-188.
16. Tamura K, Shimaoka K, Friedman M (1981) Thyroid abnormalities associated with treatment of malignant lymphoma. Cancer 47: 2704-2711.
17. Nemecek ER, Green DJ, Fisher DR, Pagel JM, Lin Y, Gopal AK, Durack LD, Rajendran JG, Wilbur DS, Nilsson R, Sandberg B, Press OW (2008) Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies. Cancer Biother Radiopharm 23: 181-191.
18. Hwang YC, Kim TY, Kim WB, Shong YK, Yi KH, Shong M, Jo YS, Kim WS, Chung JH (2009) Clinical characteristics of primary thyroid lymphoma in Koreans. Endocr J 56: 399-405.
19. Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Patterson BJ (2003) Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 21: 4157-4164.
20. Isobe K, Kagami Y, Higuchi K, Kodaira T, Hasegawa M, Shikama N, Nakazawa M, Fukuda I, Nihei K, Ito K, Teshima T, Matsuno Y, Oguchi M; Japan Radiation Oncology Group (2007) A multicenter phase II study of local radiation therapy for stage IEA mucosa-associated lymphoid tissue lymphomas: a preliminary report from the Japan Radiation Oncology Group (JAROG). Int J Radiat Oncol Biol Phys 69: 1181-1186.
21. Weetman AP, McGregor AM (1994) Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 15: 788-830.
22. Dayan CM, Daniels GH (1996) Chronic autoimmune thyroiditis. N Engl J Med 335: 99-107.
23. Yu S, Dunn R, Kehry MR, Braley-Mullen H (2008) B cell depletion inhibits spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J Immunol 180: 7706-7713.
24. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS; Type 1 Diabetes TrialNet Anti-CD20 Study Group (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361: 2143-2152.